1 New Opportunity

Golfredo Catalani, by way of Mail Administrator golfredo at CECALC.ULA.VE
Fri Jun 18 14:29:43 EST 1999


>
> TITLE: DEVELOPMENT OF ANTI-CD30 MONOCLONAL ANTIBODY - NIH
> -------------------
> > [Federal Register: June 16, 1999 (Volume 64, Number 115)]
> >
> > National Institutes of Health
> >
> > National Cancer Institute; Development of Anti-CD30 Monoclonal
> > Antibody; for the Development of HeFi-1, Cooperative Research and
> > Development Agreement
> >
> > National Cancer Institute: Development of Anti-CD30 monoclonal
> > antibody: Opportunity for Cooperative Research and Development
> > Agreement (CRADA) for the development of HeFi-1, a murine antibody
> > that targets the CD30 transmembrane receptor expressed on activated
> > B and T lymphocytes and some tumor cells. Development activities
> > will include the humanization and/or chimerization of HeFi-1,
> > followed by the pre-clinical and clinical development of the
> > antibody. In addition, clinical studies of the murine HeFi-1 are
> > also anticipated under this CRADA.
> >
> > SUMMARY: Pursuant to the Federal Technology Transfer Act of 1986 (FTTA,
> > 15 U.S.C. 3710; and Executive Order 12591 of April 10, 1987, as amended
> > by the National Technology Transfer and Advancement Act of 1995), the
> > National Cancer Institute (NCI) of the National Institutes of Health
> > (NIH) of the Public Health Service (PHS) of the Department of Health
> > and Human Services (DHHS) seeks a Cooperative Research and Development
> > Agreement (CRADA) with a pharmaceutical or biotechnology company to
>
> URL : http://web.fie.com/htdoc/fed/nih/gen/any/proc/any/fr06169901.htm






More information about the Bio-soft mailing list